Novartis Pharmaceuticals

This study tests a new drug called ERW316, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer or other solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can help control the disease. A…

This study looks at the long-term safety and effectiveness of the drug QCZ484 in people with high blood pressure. It is for patients who already completed a previous study with QCZ484. About 323 adults will take part, and researchers will track side effects and blood pressure cha…

This study follows 36 people with spinal muscular atrophy (SMA) who receive a one-time gene therapy (ITVISMA®) injected into the spine. Researchers will track how well it improves movement and what side effects occur in everyday medical practice. The goal is to see if this treatm…

This study tests a new drug, asciminib, given with chemotherapy and then with another drug called blinatumomab, in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to find…

This study provides continued access to the drug opnurasib for people with certain lung cancers or solid tumors who are already benefiting from it in another Novartis study. About 40 participants will continue their treatment and be monitored for safety. The goal is to keep offer…

This study will follow about 160 people with Familial Mediterranean Fever or Still's disease who have been taking ILARIS (canakinumab) for at least 6 months. Researchers want to see how well the drug controls the disease over time and what treatment patterns emerge. The goal is t…

This study tests a drug called secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Participants will receive injections every two or four weeks for up to a year. The main goal is to see if the drug r…

This study tests a new treatment called DJI136 for people with extensive-stage small cell lung cancer (ES-SCLC) that has worsened after standard therapy. DJI136 uses a patient's own immune cells, modified to target a protein called DLL3 on cancer cells. The trial aims to find the…

This study tests a new inhaler called QVM149, which combines three medicines, against a standard two-medicine inhaler in teenagers aged 12 to 17 with asthma. The goal is to see if the new inhaler improves lung function and asthma control more effectively. About 304 teens will tak…

This study will check if a newer blood pressure medicine called ARNi works better than standard treatments in adults with high blood pressure living in the United Arab Emirates. About 500 people will take either ARNi or a standard drug for up to 12 weeks. The main goal is to see …

This study looks at children aged 6 to 17 with certain types of juvenile arthritis (enthesitis-related or psoriatic) who are taking secukinumab. Researchers want to see what treatment strategies doctors use after the child's disease becomes inactive, and how well the drug works o…

This study tests an oral drug called atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, over 36 weeks. Participants will take the…

This study is a post-marketing surveillance of Fabhalta (iptacopan) in Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). It aims to track side effects and how well the drug works in everyday medical practice. About 21 participants will be ob…

This study will review the medical records of about 400 adults in Kuwait who have a type of blood cancer called chronic myeloid leukemia (CML). Researchers want to learn more about the patients' backgrounds, other health problems they may have, and which treatments they received.…

This study will follow nearly 6,000 adults in Italy who are prescribed inclisiran, evolocumab, or alirocumab for high cholesterol or heart disease. Researchers want to see how consistently patients take these medications over time in everyday practice. The goal is to understand r…

This study looks at how a cancer drug called pelabresib changes the way the body processes other drugs. It involves 24 adults with advanced cancers who have no standard treatment options. Participants will take pelabresib along with other medicines to measure drug levels in the b…

This study will follow 34 adults with moderate-to-severe hidradenitis suppurativa (HS) who are taking the drug secukinumab as part of their regular care. Researchers want to see if the drug can slow or prevent the buildup of plaque in the heart arteries over 12 months. Participan…

This study looks at how eltrombopag is used in routine medical practice for adults with primary immune thrombocytopenia (ITP), a condition causing low platelet counts. Researchers will collect data from doctors in the US, UK, and Germany on about 150 patients who have already tri…

This study looks at medical records from Japan to see how consistently patients take two different cholesterol-lowering medicines, inclisiran and evolocumab, over one year. It will include about 3,600 adults with high cholesterol. The goal is to understand real-world medication h…

This study looks at medical records of 83 adults with C3 glomerulopathy (a rare kidney disease) who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year. The goal is to learn more about the types…

This study will collect information from about 753 patients with metastatic prostate cancer who receive a drug called lutetium-177 vipivotide tetraxetan. The goal is to understand how the drug is used in everyday medical practice and what outcomes patients experience. No new trea…

This study will follow about 80 adults with IgA nephropathy (a kidney disease) who are starting treatment with iptacopan or atrasentan. Researchers want to see how these drugs work in everyday medical practice, not in a controlled experiment. Each person will be observed for 24 m…